You seem to have Javascript disabled. This website needs javascript in order to function properly!

HOME
ABOUT GLEOSTINE
TREATMENT
RESOURCES
- Patient Assistance Program
- Tips for Caregivers
PRESS & NEWS
- Press Release
- Position Statements
CONTACT US

gloestine_website_image_blue_12

Home
Brain Tumor and Hodgkin’s Lymphoma
gloestine_website_image_blue_12

Leave a comment Cancel reply

Comment

Name

E-mail

About Gleostine

History of Lomustine
How Gleostine Works
NextSource Pharma

Treatment

Brain Tumor & Hodgkin’s Lymphoma
Dosing & Administration
Effectiveness & Safety

Resources

Tips for Caregivers
Patient Assistance Program

Contact Us
Privacy & Security
Terms & Conditions

Copyright^© NextSource Pharma, LLC 2017 All rights reserved.

IMPORTANT SAFETY INFORMATION

DOWNLOAD PRESCRIBING INFORMATION

Gleostine® (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.

Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of Gleostine® (see WARNINGS and ADVERSE REACTIONS).

Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose (see ADVERSE REACTIONS). At the recommended dosage, courses of Gleostine® should not be given more frequently than every 6 weeks.

The bone marrow toxicity of Gleostine® is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose (see dosage adjustment table under DOSAGE AND ADMINISTRATION)